Biotricity, Inc.

Equities

BTCY

US09074H2031

Advanced Medical Equipment & Technology

Delayed Nasdaq Other stock markets 13:01:16 2024-05-23 EDT			5-day change	1st Jan Change
1.21 ^USD	-2.42%		+14.81%	+5.22%

04-26	Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro	CI
04-19	Top Premarket Decliners	MT

Biotricity, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022

February 14, 2023 at 04:07 pm

Biotricity, Inc. reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was USD 2.46 million compared to USD 1.93 million a year ago. Net loss was USD 4.52 million compared to USD 7.11 million a year ago. Basic loss per share from continuing operations was USD 0.546 compared to USD 0.894 a year ago.
For the nine months, sales was USD 6.9 million compared to USD 5.5 million a year ago. Net loss was USD 13.99 million compared to USD 23.52 million a year ago. Basic loss per share from continuing operations was USD 1.698 compared to USD 3.324 a year ago.

Latest news about Biotricity, Inc.

Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro	04-26	CI
Top Premarket Decliners	04-19	MT
Biotricity, Inc. announced that it has received $2 million in funding	04-08	CI
Biotricity Announces Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities	04-02	CI
Biotricity, Inc. announced a financing transaction	03-24	CI
Biotricity Unveils That Improved Margins Resulted from Latest Advancements to Its Proprietary Cardiac Ai Cloud Platform and Announces Plans for Continued Expansion of Its Cardiac AI Cloud	03-12	CI
Biotricity, Inc. Solidifies It's Presence in the Healthcare Landscape	03-05	CI
Transcript : Biotricity, Inc., Q3 2024 Earnings Call, Feb 21, 2024	02-21
Biotricity, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-20	CI
Biotricity Inc. Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 Billion Heartbeats	01-23	CI
HC Wainwright Downgrades Biotricity to Neutral From Buy	11-20	MT
Transcript : Biotricity, Inc., Q2 2024 Earnings Call, Nov 14, 2023	11-14
Biotricity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-14	CI
Biotricity Releases Another Groundbreaking Product: Biotres Pro	23-10-31	CI
Biotricity Files Patent for Wearable Heart Monitoring Device Bioheart	23-10-10	MT
Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device	23-10-10	CI
Biotricity, Inc. Announces Patent Filing for Cutting-Edge Biotres Device	23-10-03	CI
Transcript : Biotricity, Inc., Q1 2024 Earnings Call, Aug 15, 2023	23-08-15
Biotricity, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Biotricity Expands Amazon, Google Partnership for Remote Cardiac Monitoring Technology	23-07-25	MT
Biotricity Inc. Expands Its Proprietary AI Model and Deepens Relationship with Amazon Aws and Google's Tensor Flow for Remote Cardiac Care Applications	23-07-25	CI
HC Wainwright Adjusts Biotricity Price Target to $4 From $12 After 1-for-6 Reverse Stock Split, Maintains Buy Rating	23-07-07	MT
Biotricity, Inc. Provides Earnings Guidance for the First Fiscal Quarter Ended June 30, 2023	23-07-06	CI
HC Wainwright Adjusts Biotricity Price Target to $4 From $12, Maintains Buy Rating	23-07-05	MT
Monday's Top Decliners	23-07-03	MT

Chart Biotricity, Inc.

Duration

Period

More charts

Company Profile

Biotricity Inc. is a medical technology company focused on biometric data monitoring and diagnostic solutions. The Company developed its Bioflux technology, comprised of a monitoring device and software components. The Bioflux device is comprised of a wet electrode worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patientâs electrocardiogram (ECG) data for monitoring and diagnostic purposes. Its Bioflux platform has a built-in cellular chipset and a real-time embedded operating system, which allows for its technology to be utilized as an Internet of Things (IoT) platform. It has developed several technologies, including Biotres, Bioheart, and Biocare. Biotres is an ECG Holter solution that addresses the limitations of existing solutions in the Holter market. Bioheart is a personal cardiac monitoring solution for consumers. Biocare is a cardiac disease management platform for chronic care management and remote patient monitoring.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-19 - Q4 2024 Earnings Release (Projected)

More about the company